New York, New York - August 1, 2012 (Investorideas.com Newswire, Biotechindustrystocks.com) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for Sunshine Biopharma Inc. (OTCBB: SBFM). The stock is trading up at $0.4250, gaining $0.0750 or 21.43% on over 70,000 shares.

The Company's most recent news was July 20th when it reported it had engaged Beta Pharma Canada Inc. to manufacture an initial batch of Adva-27a and provide synthesis parameters for future scale-up and large scale manufacturing of the drug.

New York, NY - July 31, 2012 - (Investorideas.com Newswire, www.biodefensestocks.com) Investorideas.com, a leader in research for independent investors issues a trading alert for biodefense stock, PositiveIDCorporation (OTCBB: PSID), following recent news and developments for its M-BAND System for biothreat detection.

The stock closed trading on July 30th at $0.0260, gaining $0.0030, or 13.04% on over 1.9 Million shares. The Company recently reported it added Dr. Kimothy Smith as Chief Technology Advisor to the Company and its Microfluidic Systems ("MFS") subsidiary.

NOVAVAX Provides Update on Influenza Programs

    Primary Endpoints Achieved in Phase II Seasonal Influenza Trial
    Two H5N1 Pandemic Influenza Trials Fully Enrolled

Novavax, Inc. (NVAX) today reported positive top-line results from the company's Phase II clinical trial of its quadrivalent seasonal influenza virus-like particle (VLP) vaccine candidate. The study's primary objectives of demonstrating safety and immunogenicity of three ascending dose levels of the quadrivalent influenza vaccine were achieved. The VLP vaccine candidate demonstrated immunogenicity against all four viral strains based on hemagglutination inhibition assay (HAI) responses at day 21, was also well-tolerated with no vaccine-related serious adverse events observed and reactogenicity was considered acceptable. Additional safety and immune response follow-up is continuing through six months post-treatment.

Sarepta Therapeutics Announces Significant Clinical Benefit With Eteplirsen After 36 Weeks in Phase IIb Study for the Treatment of Duchenne Muscular Dystrophy

Eteplirsen Treatment Results in Benefit of 69 Meters in 6-Minute Walk Test Over Placebo/Delayed Treatment Cohort; No Eteplirsen-Related Adverse Events Through Week 36

Sarepta Therapeutics (SRPT), a developer of innovative RNA-based therapeutics, today announced that treatment with its exon-skipping compound, eteplirsen, achieved a significant clinical benefit on the primary clinical outcome, the 6-minute walk test (6MWT), over a placebo/delayed treatment cohort in a Phase IIb trial in Duchenne muscular dystrophy (DMD) patients. Eteplirsen administered once weekly at 50mg/kg over 36 weeks resulted in a 69.4 meter benefit compared to patients who received placebo for 24 weeks followed by 12 weeks of treatment with eteplirsen in the open-label extension.